Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Effect of Rivoceranib 200 mg Once Daily on the Pharmacokinetics of a Cocktail Probe Substrate of Cytochrome P450 Enzymes: A Phase I Trial in Healthy Volunteers

D. Nguyen X. Wei Xianzhang Meng Laura Alexander Kristin Ryan Seong Jang
Aug 2026 · Clinical Pharmacokinetics · Vol 65, pp. 1565 - 1574 · 0 citations · 32 references
Medicine

TL;DR

Rivoceranib 200 mg QD may substantially inhibit the metabolism of CYP2D6 substrates, and concomitant use of CYP2D6 substrate drugs with rivoceranib should be approached with caution, and dose adjustment of substrates of CYP2D6 may be necessary when co-administration cannot be avoided.

DOI PubMed Semantic Scholar
View source

Similar papers

Clinical trial Open access Sep 2026

Evaluating the Impact of CYP1A2 Inhibition on the Pharmacokinetics of Savolitinib: A Phase 1 Open‐Label Study

Savolitinib is an oral, potent, selective CNS‐penetrant MET‐tyrosine kinase inhibitor that in vitro studies indicate is metabolized by cytochrome P450 (CYP) enzymes, including CYP1A2, and by non‐CYP enzymes, such as aldehyde oxidase (AO). Savolitinib primary metabolites, M2 and M3, are formed mainly by CYP1A2 and AO, r...

Kowser Miah, Jitendar Reddy, Pradeep Sharma et al. · 0 citations
Open access Sep 2026

Evaluation of the Effect of Cendakimab on the Pharmacokinetics of CYP Probe Drugs in Patients With Eosinophilic Esophagitis

Cendakimab had no clinically meaningful effects on cytochrome P450 enzyme activities and was generally safe and well tolerated with or without probe substrates in adults with active eosinophilic esophagitis.

Pei-Jin Zhang, C. Charriez, Bindu Murthy et al. · 0 citations
Clinical trial Open access Sep 2026

BV100 (rifabutin IV) drug interaction studies in healthy subjects with index CYP450 3A probes midazolam and itraconazole

BV100 is a mild/weak CYP3A enzyme inducer and a mild substrate for CYP3A inhibitors, however, co-administration with strong CYP3A inhibitors resulted in a disproportionate increase in exposure to the active metabolite 25-O-desacetyl rifabutin, leading to an ∼2-fold increase in total active-moiety exposure.

Pierre Delique, C. Kemmer, Lisa Husband et al. · 0 citations
Sep 2026

Pharmacokinetic and safety interactions between aildenafil and clarithromycin, cimetidine, or rifampin in healthy subjects.

AIMS Aildenafil citrate, an orally bioavailable phosphodiesterase type 5 (PDE5) inhibitor, is primarily metabolized by cytochrome P450 3A4 (CYP3A4). This study aimed to assess potential pharmacokinetic interactions between aildenafil citrate tablets and cytochrome P450 (CYP)3A modulators. METHODS This study involved...

Ran Xie, Nan Zhao, B. Jia et al. · 0 citations
Oct 2026

Predicting drug-drug interaction and optimal dosing regimens of rivaroxaban combined with ceritinib using physiologically based pharmacokinetic and pharmacodynamic modeling.

The authors' model predicts that ceritinib co-administration substantially elevates rivaroxaban exposure and exploratory major bleeding risk, and predicts model-predicted dosing strategies comparable to standard monotherapy.

Jian-Wei Ren, Yi-Yao Li, Xin Zheng et al. · 0 citations
Open access Sep 2026

Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Rivaroxaban with Cobicistat or Darunavir/Cobicistat in Healthy Participants.

BACKGROUND Direct oral anticoagulants such as rivaroxaban are a feasible and convenient option for anticoagulation in people living with HIV. Here, we assess the effect of cobicistat or darunavir/cobicistat on the pharmacokinetics (PK), pharmacodynamics (PD), and safety of rivaroxaban. METHODS This open-label, fixed...

Lilian W. Adeojo, Cheryl Pauls, Doris Z. Swaim et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.